Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CELZ-100
- Development stage
- Preclinical
- Lead developer
- Creative Medical Technology
- Modality
- Vaccines & Immunotherapeutics, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Other Cell Types → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous (re-injection Of Autologous Modified Immune Cells)
01
Overview
CELZ-100 (ImmCelz) is an autologous cell-based immunotherapy developed by Creative Medical Technology Holdings. It utilizes a proprietary, cell-free system to "supercharge" a patient's own immune cells using secreted factors from perinatal tissue-derived cells (AlloStem platform). The process involves harvesting the patient’s immune cells, incubating them with a reprogramming cocktail derived from donor stem cells, and then reinjecting these "supercharged" immune cells back into the patient. These modified immune cells are designed to educate other components of the immune system to halt autoimmune attacks while preserving normal pathogen defense. The primary indication under development is brittle type 1 diabetes; additional potential indications include heart disease, liver disease, and kidney disease[1][4][5]. The mechanism includes modulation of regulatory T lymphocytes and hepatocyte growth factor pathways[6].
- Brand names
- ImmCelz
- Other names
- CELZ-100CELZ100CELZ 100ImmCelz
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on CELZ-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CELZ-100.